Resverlogix Announces Receipt Of Notice Of Allowance From The United States Patent And Trademark Office

Published: Mar 15, 2017

CALGARY, March 15, 2017 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today announced the receipt of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent claims covering the use of apabetalone in combination with Rosuvastatin in the United States. Rosuvastatin was exclusively marketed by AstraZeneca under the trade name Crestor® until its patent expired in 2016. The allowed patent is entitled: "Compositions and Therapeutic Methods for Accelerated Plaque Regression," and covers claims for both a single composition as well as separate compositions of the two drugs.  Resverlogix has similar claims pending in other jurisdictions.

"We are very pleased with the allowance of one of the key patents, covering the combination of apabetalone with one of the most successful statins on the market.  It further solidifies Resverlogix as a key player in the cardiovascular disease market," stated Donald McCaffrey, President & Chief Executive Officer.

Mr. McCaffrey further stated, "Resverlogix devotes significant resources to ensure the protection of ideas and inventions related to the core areas of our business. We believe that our know-how in multiple disease areas will provide a significant competitive advantage. We intend to continue to develop and protect our proprietary tools, methods, and trade secrets." 

About Resverlogix

Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the first and only BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with diseases such as high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, Alzheimer's disease, Orphan diseases, and peripheral artery disease, while maintaining a well described safety profile. Apabetalone is the only selective BET bromodomain inhibitor in human clinical trials, currently in a Phase 3 trial BETonMACE in high-risk CVD patients with type 2 DM and low high-density lipoprotein (HDL).

Resverlogix common shares trade on the Toronto Stock Exchange (TSX: RVX).

Follow us on Twitter: @Resverlogix_RVX (, or on our blog at

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information relating to the Company's intellectual property and patent claims covering the use of apabetalone in combination with Rosuvastatin, Phase 2 Renal Impairment trial and Phase 3 clinical trial, and the potential role of apabetalone in the treatment of CVD, DM, chronic kidney disease, Alzheimer's disease, Orphan diseases, and peripheral artery disease. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information please contact:

Investor Relations
Phone: 403-254-9252
Or visit our website:

SOURCE Resverlogix Corp.

Back to news